NYSE:NGVT - Ingevity Stock Price, Forecast & News

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity Corp (NYSE:NGVT) released its quarterly earnings data on Monday, February, 3rd. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.07. The business earned $303.40 million during the quarter, compared to analyst estimates of $305.09 million. Ingevity had a return on equity of 51.91% and a net margin of 14.21%. The company's revenue was up 8.9% compared to the same quarter last year. During the same period last year, the company posted $1.07 EPS. View Ingevity's Earnings History.

Ingevity is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Ingevity.

Ingevity updated its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.3-1.35 billion, compared to the consensus revenue estimate of $1.33 billion.

8 Wall Street analysts have issued 12 month price objectives for Ingevity's stock. Their forecasts range from $67.00 to $130.00. On average, they expect Ingevity's share price to reach $102.75 in the next twelve months. This suggests a possible upside of 111.1% from the stock's current price. View Analyst Price Targets for Ingevity.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ingevity.

News stories about NGVT stock have trended extremely negative on Thursday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ingevity earned a daily sentiment score of -4.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Ingevity.

Some companies that are related to Ingevity include Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Balchem (BCPC), Chemours (CC), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Costco Wholesale (COST), NVIDIA (NVDA), Alibaba Group (BABA), General Electric (GE), Quaker Chemical (KWR), Westrock (WRK) and Paypal (PYPL).

Ingevity's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (3.22%), State Street Corp (3.15%), Massachusetts Financial Services Co. MA (2.61%), Victory Capital Management Inc. (1.96%), Goldman Sachs Group Inc. (1.96%) and Alliancebernstein L.P. (1.93%). Company insiders that own Ingevity stock include D Michael Wilson, John C Fortson, Katherine Pryor Burgeson and Phillip John Platt. View Institutional Ownership Trends for Ingevity.

NGVT stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Capital Research Global Investors, Panagora Asset Management Inc., Amundi Pioneer Asset Management Inc., Moody Aldrich Partners LLC, Mesirow Financial Investment Management Equity Management, Marshall Wace North America L.P. and Chartwell Investment Partners LLC. View Insider Buying and Selling for Ingevity.

NGVT stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Artisan Partners Limited Partnership, Scopus Asset Management L.P., Pictet Asset Management Ltd., California Public Employees Retirement System, Massachusetts Financial Services Co. MA, Thrivent Financial for Lutherans and UBS Group AG. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson and John C Fortson. View Insider Buying and Selling for Ingevity.

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NGVT stock can currently be purchased for approximately $48.67.

Ingevity has a market capitalization of $2.04 billion and generates $1.29 billion in revenue each year. The company earns $183.70 million in net income (profit) each year or $4.93 on an earnings per share basis. Ingevity employs 1,750 workers across the globe.View Additional Information About Ingevity.

The official website for Ingevity is http://www.ingevity.com/.

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]